Navigation Links
Cryo-Cell International, Inc. Reports Third Quarter 2007 Results
Date:10/15/2007

/p>

Forward-Looking Statement

Statements wherein the terms "believes", "intends", "projects" or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the uncertainty of market acceptance of any potential service offerings relating to maternal placental stem cells (MPSCs) and other types of stem cells other than cord blood stem cells, given that such new stem cells have not yet been used in human therapies, and treatment applications using such stem cells are subject to further research; need to complete certain developments, including completion of clinical validation and testing for commercialization of the processes for the MPSC service and other services and the Company's development of its final business and economic model in offering any such service; any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our new facility; any technological breakthrough or medical breakthrough that would render the Company's business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the c
'/>"/>

SOURCE Cryo-Cell International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)KANSAS CITY, Mo., Dec. 4 The large, two-day free health clinic sponsored by the National Association of Free Clinics (NAFC) in Kansas City on Wednesday and Thursday is not just for the sick but also
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
Breaking Medicine News(10 mins):Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2
...icials across UK are participating in a dummy exer...y bird flu pandemic. The preparation may be s...n Britain are wary of a bird flu epidemic hitting ... chiefly in birds, but infections with these virus...
...s have developed an experimental vaccine that redu...d with cytomegalovirus// (CMV). This virus also ca...n children infected in early fetal life. The Natio... no vaccine or treatment for pregnant women who ha...
...er Anoushka Shankar has become the first Indian ce...o fight against hunger in India//. She joins...ollywood star Drew Barrymore and footballer Ronald...ause. I will personally do whatever I can to raise...
... a haven for migratory birds, is gearing up to tac...ases// of the deadly virus. "We are watching...industry to take certain protective measures," sai...lu had been reported yet from any part of the stat...
...ounterfeit drugs are being circulated in South Asi...ingitis, typhoid//, pneumonia and avian flu. Accor...iane, the drugs have been well disguised making it... treated with the original drug. They also add tha...
...to a report released by International Federation o...a has been hit by measles//. This disease has so f...people are said to be affected by this illness. ... cases pointing to the spread of the disease. The ...
Other Medicine News:Health News:Dummy Emergency Operation Launched 2Health News:CMV Vaccine Prototype Successfully Tested in Guinea Pigs 2Health News:CMV Vaccine Prototype Successfully Tested in Guinea Pigs 3
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
(Date:12/3/2009)WARRENDALE, Pa., Dec. 3 Radiology imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago. The Co
(Date:12/3/2009)FORT WORTH, Texas, Dec. 3 Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a rapidly growing provider of specialty medical products, announced today an agreement with the Health In
Breaking Medicine Technology:Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3West Announces Third Quarter 2009 Results 5943 1West Announces Third Quarter 2009 Results 5943 2West Announces Third Quarter 2009 Results 5943 3West Announces Third Quarter 2009 Results 5943 4West Announces Third Quarter 2009 Results 5943 5West Announces Third Quarter 2009 Results 5943 6West Announces Third Quarter 2009 Results 5943 7West Announces Third Quarter 2009 Results 5943 8West Announces Third Quarter 2009 Results 5943 9West Announces Third Quarter 2009 Results 5943 10West Announces Third Quarter 2009 Results 5943 11West Announces Third Quarter 2009 Results 5943 12West Announces Third Quarter 2009 Results 5943 13West Announces Third Quarter 2009 Results 5943 14West Announces Third Quarter 2009 Results 5943 15West Announces Third Quarter 2009 Results 5943 16West Announces Third Quarter 2009 Results 5943 17West Announces Third Quarter 2009 Results 5943 18West Announces Third Quarter 2009 Results 5943 19West Announces Third Quarter 2009 Results 5943 20West Announces Third Quarter 2009 Results 5943 21West Announces Third Quarter 2009 Results 5943 22Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 1Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 2Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 3Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 4Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 5Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 6Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 7Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 8Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 9Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 10Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 11Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 12Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 13Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 14Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 15Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 16Experimental Stem Cell Therapy Raises Hope for Pulmonary Fibrosis Patients 14698 1Experimental Stem Cell Therapy Raises Hope for Pulmonary Fibrosis Patients 14698 2Experimental Stem Cell Therapy Raises Hope for Pulmonary Fibrosis Patients 14698 3
...48-week investigational regimen yielded nearly dou...ate on next-generation HCV protease inhibitor SCH ...HAGEN, Denmark, April 23 Schering-Plough Corporat...ts of the HCV SPRINT-1 study showed boceprevir, it...tor, in combination with peginterferon alfa-2b and...
... , , , FDA approval for testing in humans water..., , ROCKVILLE, Md., April 23 In a move that high...n in tackling international health challenges, the... from the PATH Malaria Vaccine Initiative (MVI), h... tests in adult volunteers -- of its unique malari...
Other Medicine Technology:Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 2Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 3Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 4
...G-9200 is a Windows 2000 PC based EEG with high pe... and software. EEG-9200 provides high quality perf...in the sleep lab or EEG lab. Quality EEG recording...CU. Neurofax has high performance, high sensitivit...
...act is the first magnetic stimulator to offer the ... stimulation. It is designed to provide the simple...tic routine (at the same time, it may also help re...ons without moving away from your patient). , ,...
Fidelity IAB Intra-Aortic Balloon Catheter
...series is a new top-line range of digital pacemake...rillation (AF). Because the T-series combines digi...reatment of AF is taken one step further. Thanks t...ored continuously and extensively. This gives phys...
Medicine Products: